LIDDS Lidds AB

LIDDS: Liproca® Depot Phase IIb results to be presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019

LIDDS: Liproca® Depot Phase IIb results to be presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019

Professor Laurence Klotz, a world leading expert in Active Surveillance of prostate cancer patients, will present the results of the LPC-004 prostate cancer study at the 11th European Multidisciplinary Congress on Urological Cancers, EMUC19. The oral presentation is scheduled for November 16, 2019.

Professor Klotz is one of the LPC-004 study investigators and is Professor at the University of Toronto Division of Urology at the Sunnybrook Health Sciences Centre in Canada.

-I am very pleased that the Phase IIb study results will be presented at EMUC by the expert and key opinion leader Professor Klotz, says Monica Wallter, CEO, LIDDS.

LIDDS will announce the preliminary results of the LPC-004 study in September. The final study report is scheduled for the last quarter of 2019.

For additional information, please contact: 

Monica Wallter, CEO, LIDDS   +46 (0)737 07 09 22  

About LIDDS AB (publ)

LIDDS AB (publ) is a Swedish-based pharmaceutical company with a unique drug delivery technology: NanoZolid®. NanoZolid® is clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid® is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS shares (LIDDS) are listed on Nasdaq First North. Redeye AB, , +46 (0)8 121 576 90, is a certified adviser to LIDDS. For more information, please visit  

Attachment

EN
28/08/2019

Underlying

LIDDSLidds AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lidds AB

 PRESS RELEASE
Free
LIDDS LIDDS AB

Report from Extraordinary General Meeting in LIDDS

Report from Extraordinary General Meeting in LIDDS UPPSALA, SWEDEN – LIDDS AB (publ)’s (“LIDDS” or the “Company”) Extraordinary General Meeting was held 11 March 2022 in the Company’s premises in Uppsala. The Extraordinary General Meeting resolved as set out below. Authorisation to issue convertiblesThe Extraordinary General Meeting resolved in accordance with the Board of Directors’ proposal to authorise the Board of Directors to, within the scope of the articles of association, with deviation from the shareholders’ pre-emption rights, on one or several occasions during the period un...

March 11, 2022 1 EN
 PRESS RELEASE
Free
LIDDS LIDDS AB

Kommuniké från extra bolagsstämma i LIDDS

Kommuniké från extra bolagsstämma i LIDDS UPPSALA, SVERIGE – LIDDS AB (publ) (”LIDDS” eller ”Bolaget”) höll den 11 mars 2022 extra bolagsstämma i Bolagets lokaler i Uppsala. Den extra bolagsstämman beslutade enligt nedan. Bemyndigande att emittera konvertiblerDen extra bolagsstämman beslutade i enlighet med styrelsens förslag att bemyndiga styrelsen att inom ramen för gällande bolagsordning, med avvikelse från aktieägarnas företrädesrätt, vid ett eller flera tillfällen intill nästkommande årsstämma, fatta beslut om emission av konvertibler i Bolaget. Sådan emission ska endast kun...

March 11, 2022 1 EN
 PRESS RELEASE
Free
LIDDS LIDDS AB

LIDDS publishes agenda for the company's Capital Markets Day 2022

LIDDS publishes agenda for the company's Capital Markets Day 2022 UPPSALA, SWEDEN – LIDDS AB (publ) announced today the agenda for the Capital Markets Day to be held on March 9, 2022, for investors, analysts and media. Agenda Capital Markets Day 2022 15.00-15.10 Welcome - Nina Herne, CEO15.10-15.45 Presentation of LIDDS company strategy and drug delivery technology - Nina Herne, CEO15.45-16.45 Update on LIDDS pipeline and clinical programs - Johan Harmenberg, CMO16.45-16.55 Break16.55-17.15  Financial update - Jenni Björnulfson, CFO17.15-18.00 Q&A session - Nina He...

March 4, 2022 1 EN
 PRESS RELEASE
Free
LIDDS LIDDS AB

LIDDS publicerar agenda för bolagets kapitalmarknadsdag 2022

LIDDS publicerar agenda för bolagets kapitalmarknadsdag 2022 UPPSALA, Sverige – LIDDS AB (publ) meddelade i dag agendan för den kapitalmarknadsdag som kommer att arrangeras den 9 mars 2022 för investerare, analytiker och media. Agenda Kapitalmarknadsdag 2022 15.00-15.10 Välkomnande - Nina Herne, vd15.10-15.45 Presentation av LIDDS uppdaterade strategi och bolagets drug delivery-teknologi - Nina Herne, vd15.45-16.45 Uppdatering kring LIDDS projektportfölj och kliniska program - Johan Harmenberg, CMO16.45-16.55  Paus16.55-17.15   Finansiell uppdaterin...

March 4, 2022 1 EN
 PRESS RELEASE
Free
LIDDS LIDDS AB

Complement to press release: Notice of Extraordinary General Meeting o...

Complement to press release: Notice of Extraordinary General Meeting of LIDDS AB (publ) In the press release published on February 22, 2022, the appendix with the notice was missing. The notice is attached to this press release, which otherwise corresponds with the previously issued press release. The supplement was submitted for publication on February 24, 2022. Notice of Extraordinary General Meeting in LIDDS AB (publ) The shareholders in LIDDS AB (publ) (reg. no. 556580-2856) (the “Company” or “LIDDS”) are hereby convened to the Extraordinary General Meeting on Friday, 11 March 202...

February 24, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch